1. Baseline data not pertaining to family history re	corded at recru	iitment					
Name							
Address 1							
Address 2							
Address 3							
Address 4							
Postcode							
NHS number							
Hospital Number							
Study number (Study number as used by centre)							
Date of birth							
Date of recruitment (Date consent form signed)							
BRCA1 mutation identified in family	Not tested	Positive		Negative	Negative		
BRCA2 mutation identified in family	Not tested	Positive		Negative		Unknown	
Personal search (If yes to either of above, has subject been tested for relevant mutation)	Yes		No	No		Unknown	
Personal BRCA status (If yes, to above, was subject positive for relevant mutation?)	Yes		No		Unknown		
Menopausal status	Pre (regular periods) Post (>12 months since last period)			Peri- (7–12 months since last period)			
				Unknown			
Age at menopause (years) (0 if pre- or perimenopausal)							
Age at hysterectomy/opherectomy (years)							
HRT use	Never Previously						
	Currently			Unknown			
Parity (Number of pregnancies to at least 30 weeks)							
Age at first pregnancy (Age at first pregnancy of at least 30 weeks duration)							
Age at menarche							
Previous screening mammography	Yes No		N/K		Ϋ́Κ		
Time since last mammogram (Months)							
Previous Breast biopsy?	No			ADH			
	LCIS		Benign NOS				
Previous breast surgery? (Yes/no)	Yes No		N,		Ϋ́Κ		
How many sisters has the participant?							
How many sisters has the participant's mother?							
How many sisters has the participant's father?							
Has the family history data been verified from medical records?	Yes	1	No		N/	ſΚ	

1a. Family history of breast and ovarian cancer taken at baseline – list only relatives with a diagnosis							
Relative (first or second degree only)	Maternal or paternal	Breast cancer (Y/N)	Bilateral (Y/N)	Age first diagnosed	Ovarian cancer (Y/N)	Age first diagnosed	

2. Screening and assessment data recorded Name		rscreening	-episode-			
NHS number						
Screening Centre						
Study number						
Date of mammogram						
Screening round	1	2	3	4	5	6
Suspicion left breast (5 point score)						
Suspicion right breast (5 point score)						
Mammographic pattern (Fatty/mixed/dense)						
Recall for assessment (Yes/No)						
Percutaneous biopsy (Yes/No)						
Physical examination – not done (1) done after mammography result (2) done before mammography result (3) mammography and physical examination results each assessed with knowledge of the other (4)						
Ultrasound scan performed – not done (1) done after mammography result (2) done before mammography result (3) mammography and USS results each assessed with knowledge of the other (4)						
Palpable lump (Yes/No)						
Other tests 1						
Other test 1 result						
Other tests 2						
Other test 2 result						
Surgery/open biopsy (Yes/No)						
Final diagnosis (Breast cancer, BBD, normal- if cancer, form below required)						

3. Cancer data – all cancers, whether detected by screening or clinically	
Name	
NHS number	
Screening Centre	
Study number	
Date of diagnosis (Date of surgery, or date of most definitive test otherwise)	
Mode of detection (Prevalence screen, incidence screen, interval cancer, clinically diagnosed after non-attendance at last scheduled screen)	
Date of mammogram (prompting diagnosis if screen detected)	
Date of last scheduled mammogram (if clinically detected)	
Date of last actual mammogram (if clinically detected)	
Tumour palpable (on physical examination)	
Symptoms (yes/no)	
Invasive or in situs	
Neoadjuvant chemotherapy Preoperative chemotherapy (yes/no)	
Tumour size Pathological size of invasive component (mm)	
Lymph nodes examined Number of lymph nodes examined pathologically	
Lymph nodes positive (Number of pathologically examined nodes with tumour)	
Axillary surgery (None, sentinel only, sampling, clearance (either immediately or after positive sentinel finding))	
Histological grade (1, 2 or 3)	
Histological type (DCIS, invasive ductal, lobular, medullary, tubular, mucinous)	
Ultrasound size (Ultrasonically assessed size, if pathology not available (mm))	
Mammographic size (if pathology and ultrasound size both unavailable (mm))	
Surgery (None, local excision, mastectomy)	
Radiotherapy (Yes/no)	
Hormone therapy (Yes/no)	
Chemotherapy (Yes/no)	

3. Cancer data – all cancers, whether detected by screening or clinically				
Oestrogen receptor status (Positive/negative)				
Progesterone receptor status (Positive/negative)				